

# WFS1 A95D — Wolframin

Alanine → Aspartic acid at position 95. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.994, DynaMut2  $\Delta\Delta G$  -1.47 kcal/mol (destabilising).

## IDENTITY

Variant	A95D (p.Alanine95Aspartic acid)
DNA change	c.284C>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001473915
Amino acid change	Alanine (A) → Aspartic acid (D)

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 95	<b>89.81</b> HIGH CONFIDENCE
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT well above 50 threshold

Position 95 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is negatively charged (aspartate — carboxylate). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.994**am\_class: **likely pathogenic** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-1.47** kcal/molDestabilising · Job  
178092087522

PLDDT (ALPHAFOLD)

**89.81**

high confidence

## CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE
Review status	criteria provided, single submitter
Last evaluated	2022/08/10 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	A95D is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none"><li>(no conditions catalogued)</li></ul>

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected  $\rightarrow$  CATEGORY 3 – docking experiments  $\Delta\Delta G 2-4 \rightarrow$  CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4 \rightarrow$  CATEGORY 1 – gene therapy pLDDT  $< 50 \rightarrow$  CATEGORY 5 – IDR, experimental only Stable fold + functional site hit  $\rightarrow$  CATEGORY 4 – site-specific docking

### Category 3/4 — Most Druggable

$|\Delta\Delta G|=1.47 < 2$  kcal/mol (fold intact) + AlphaMissense 0.994 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution ( $|\Delta\Delta G|=1.47$  kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.994. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.